Clinical Trial · NCT04928820

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

Overview

This phase II trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in detecting the spread of cancer to the bones (bone metastasis) in patients with prostate cancer and increased PSA after treatment (biochemical recurrence) during androgen deprivation therapy. Diagnostic procedures, such as 68Ga-PSMA-11 PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Phase 2

Contacts

Jeremie Calais, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04928820

Drug / Compound

PSMA-11

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: HBED-CC

Eligibility

Inclusion

Patient with biochemical progression during ADT or combination therapies including ADT who are referred for imaging evaluation (prostate specific antigen \[PSA\] level \>= 1 ng/ml that has increased on at least 2 successive occasions at least 1 weak apart)
Within 30 days of the PSMA PET, without any new prostate cancer (PCa) therapy in between

Exclusion

Initiation of a new therapy between the PSMA PET/CT and the bone scans

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…